Koninklijke Philips N.V. (PHG) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects a mixed outlook: strong order growth and margin improvements indicate potential positives, but uncertainties around tariffs and vague management responses about future challenges temper enthusiasm. The Q&A reveals concerns about flat growth in China and potential headwinds from tariffs. The financial performance and strategic updates are not strong enough to drive a significant stock movement, thus a neutral sentiment is appropriate.
Key Financial Performance
Order Intake Order intake was strong, up 7%, reflecting sustained improvement over the past year as we continue to expand and grow our order book, strengthening visibility into 2026 and beyond.
Comparable Sales Growth Comparable sales growth of 7% year-on-year and was broad-based across all businesses and geographies and strong contributions from Personal Health and Connected Care businesses continued.
Adjusted EBITDA Margin (Q4) Adjusted EBITDA margin improved by 160 basis points to 15.1% despite the impact from tariffs.
Adjusted EBITDA Margin (Full Year) Adjusted EBITDA margin of 12.3%, exceeding our outlook, and that's despite the impact of incremental tariffs. These results reflect margin accretive innovation, productivity gains and disciplined execution.
Equipment Order Intake Equipment order intake grew 7%, reflecting sustained momentum over the past year. Growth was broad-based across D&T and Connected Care, driven by sustained double-digit growth in North America.
D&T Order Intake D&T order intake up 5% and Connected Care up 7%. Order book grew 5% year-on-year with inherent quarterly unevenness.
Image-Guided Therapy Order Intake Image-Guided Therapy achieved strong order intake growth and Precision Diagnosis returned back to growth. Results were driven by strong demand for our high end Azurion 7 interventional platform, the EPIQ CVx ultrasound for cardiovascular imaging and continued successful ramp-up of our CT 5300.
Connected Care Sales Growth Connected Care closed the year with strong momentum, delivering comparable sales growth of 7% in the fourth quarter and 3% for the full year. Fourth quarter performance was driven by double-digit growth in Monitoring and mid-single-digit growth in Enterprise Informatics, driven by robust order book conversion in North America.
Personal Health Sales Growth Personal Health comparable sales growth improved sequentially, growing 14% in the fourth quarter and 8% for the full year, with all 3 businesses contributing. Growth was broad-based across geographies.
Adjusted EBITDA Margin (Personal Health) Adjusted EBITDA margin in Personal Health improved 500 basis points to 23% in the fourth quarter, driven by sales growth and productivity measures, partially offset by tariffs and cost inflation. For the full year, adjusted EBITDA margin increased by 130 basis points to 18%.
Group Comparable Sales Growth Comparable sales growth accelerated to 7% in the fourth quarter, with broad-based growth across business segments and geographies, led by strong performance from North America. For the full year, comparable sales growth of 2.3% was in line with our outlook.
Group Adjusted EBITDA Margin Adjusted EBITDA margin expanded 160 basis points year-on-year to 15.1% in Q4 and for the full year, increased 80 basis points to 12.3%. This performance more than offset incremental tariff headwinds, which came in slightly better than our expected EUR 150 million to EUR 200 million range after substantial mitigation.
Productivity Savings In Q4, we delivered EUR 248 million in productivity savings, bringing total savings to EUR 815 million for the year, in line with our outlook. Since 2023, our cost management and productivity initiatives delivered more than EUR 2.5 billion, exceeding our original outlook of EUR 2 billion by the end of 2025.
Net Income Net income increased to EUR 397 million in the quarter, primarily reflecting improved income from operations and lower tax charges.
Free Cash Flow We generated EUR 1.2 billion of free cash flow this quarter. This was EUR 85 million lower year-over-year, reflecting a tougher comparison base as Q4 2024 included a EUR 367 million Respironics insurance receipt. For the full year, free cash flow was ahead of our outlook, driven by higher earnings, reaching EUR 512 million after the payment of approximately EUR 1 billion in cash related to U.S. medical monitoring and personal injury settlements in the first quarter of 2025.
Leverage Ratio Our leverage ratio improved to 1.7x on a net debt to adjusted EBITDA basis from 2.2x in Q3 and 1.8x in Q4 2024, driven by higher earnings and stronger cash balances.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Azurion 7 interventional platform: Strong demand for this high-end platform contributed to growth in Image-Guided Therapy.
EPIQ CVx ultrasound: Used for cardiovascular imaging, it showed strong demand.
CT 5300: Continued successful ramp-up in demand.
Helium-free 3T MRI: Launched as the world's first helium-free MRI system.
Verida: Introduced as the world's first AI detector-based always-on spectral CT system.
LumiGuide: Launched as the first real-time AI-enabled light-based 3D navigation solution integrated with Azurion.
OneBlade shavers and premium portfolio: Strong demand for high-end shavers, IPL hair removal devices, and oral health care products.
Sonicare Prestige 9900 and Norelco i9000 Prestige: Debuted in China, showcasing commitment to locally relevant innovation.
North America: Sustained double-digit order intake growth driven by strong hospital demand and investments in secure, productivity-enhancing platforms.
China: Tender activity increased but faced challenges due to centralized procurement and competition, leading to cautious near-term outlook.
Europe: Stable capital spending with strong wins in Indonesia and India.
Quality improvements: Tangible improvements in quality performance, including CAPA timelines and reductions in nonconformances and complaints.
Supply chain resilience: Service levels at all-time highs and lead times back to competitive levels despite global trade complexities.
Productivity savings: Achieved EUR 815 million in productivity savings in 2025, exceeding the original outlook.
SpectraWAVE acquisition: Strengthens innovation leadership in cardiology interventions.
AI-enabled innovation platforms: Accelerated execution of scalable innovation platforms centered on AI.
Regionalization and localization: Focused on mitigating tariff impacts and enhancing supply chain agility.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariffs: Incremental tariffs have impacted adjusted EBITDA margins, with a net impact of EUR 250 million to EUR 300 million expected in 2026. Despite mitigation efforts, these tariffs remain a significant challenge to profitability.
Respironics Recall and FDA Warning Letter: The company continues to address the consequences of the Respironics recall and the FDA warning letter issued last October. These issues require ongoing resolution efforts and regulatory engagement, posing risks to operations and reputation.
China Market Conditions: The expansion of centralized procurement in China has led to longer processing times and tougher competition, negatively impacting market growth. Consumer sentiment in China remains cautious, with subdued demand.
Macroeconomic and Regional Challenges: Rising costs and workforce shortages in North America are driving hospital consolidation, which could impact demand dynamics. In Europe, capital spending remains stable but not growing, while in China, market growth is slow due to centralized procurement and cautious consumer sentiment.
Supply Chain Resilience: Despite improvements, the global trade environment remains complex, and the company faces challenges in maintaining supply chain resilience and mitigating tariff impacts.
Regulatory and Quality Issues: The company is working to improve quality performance, manage corrections and removals, and reduce nonconformances. However, these efforts require significant resources and pose operational risks.
Currency Volatility: Significant volatility in major currencies, particularly the U.S. dollar, poses risks to financial performance, although hedging and commercial actions have mitigated some impacts.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Order Intake: Order intake was strong, up 7%, reflecting sustained improvement over the past year as we continue to expand and grow our order book, strengthening visibility into 2026 and beyond.
Sales Growth: As we enter 2026, we are moving from a strengthened foundation and margin improvement focus into the next phase for Philips, one of profitable growth acceleration with a clear path to mid-single-digit sales CAGR and mid-teens margins by 2028.
Regional Growth: North America is expected to remain a key growth engine in 2026 and into the midterm, with sustained double-digit order intake growth. In China, sales growth is expected to be stable, while Europe shows stable capital spending. Select international regions, such as Indonesia and India, are increasing investments in healthcare and digitization.
Comparable Sales Growth: Overall, we expect comparable sales growth between the 3% to 4.5% range in 2026, led by North America and international regions.
Adjusted EBITDA Margin: Adjusted EBITDA margin is expected to improve to 12.5% to 13% in 2026, driven by growth, continued operational improvements, and further productivity, partially offset by the incremental impact of tariffs.
Tariff Costs: In 2026, tariff costs will be fully annualized, resulting in a net impact of EUR 250 million to EUR 300 million, net of substantial mitigations.
Quarterly Phasing: All 4 quarters in 2026 are expected to be within the full year comparable sales growth range of 3% to 4.5%, with Q1 at the lower end due to normal seasonality and a strong finish to 2025.
Productivity Program: A new EUR 1.5 billion productivity program for the 2026 to 2028 period is being launched, building on the EUR 2.5 billion productivity program successfully delivered in the last 3 years.
Free Cash Flow: Free cash flow is expected to be in the range of EUR 1.3 billion to EUR 1.5 billion in 2026, driven by higher earnings and lower adjusting items, partially offset by increased capital expenditure and higher income tax payments.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Option: Shareholders are offered the option to receive dividends in shares or cash.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you explain the gross margin improvement in Q4 and its impact on the 2026 margin profile?
A:Charlotte Hanneman explained that gross margin improvement was driven by innovations, productivity, and disciplined execution. Despite tariff impacts, continued margin expansion is expected in 2026, supported by annualizing tariffs, productivity, and innovation.
Q:How does the 5% order intake for D&T in 2025 differ by modality in Q4, and how does it reconcile with slower revenue performance for 2026?
A:Roy Jakobs stated that the 5% order intake was supported by strong contributions from IGT, MR, and ultrasound, with double-digit growth in North America. Slower revenue performance in 2026 is due to longer conversion cycles in D&T compared to Connected Care, but strong order momentum is expected to underpin sales growth later in the year.
Q:What buffers have been built into the 2026 guidance, particularly on margins?
A:Roy Jakobs mentioned that the 2026 guidance accounts for a dynamic environment, including tariff impacts and uncertainties. The company has adopted a more agile and lean organization to adapt quickly to changes, with growth and productivity as key contributors to margin improvement.
Q:Why was Precision Diagnostics (PD) flat in Q4 despite better order intake earlier in the year?
A:Charlotte Hanneman explained that PD sales improved sequentially but were impacted by higher exposure to China. The company has rebuilt the foundation of PD, reduced SKUs, and expects innovation and stronger execution to drive growth and margin improvement in 2026.
Q:Why is Q1 expected to be at the lower end of the 2026 growth guidance range?
A:Charlotte Hanneman stated that Q1 is typically the lowest quarter due to seasonality and strong Q4 performance. Tariffs are a significant headwind in Q1, but margin expansion is expected later in the year due to stronger sales and operating leverage.
Q:What drove the strong Q4 performance in Personal Health (PH), and is there a stocking effect?
A:Charlotte Hanneman attributed the strong 14% growth in PH to market share gains, healthy sell-out trends, resilient demand in North America, and innovations like Sonicare and OneBlade. The company also derisked China trade inventory, reducing it to 3 months.
Q:What is the update on the Section 232 investigation by the U.S. government?
A:Roy Jakobs stated that the investigation has not concluded, and no outcomes have been shared. It is seen as a potential replacement for tariffs, with no expected worsening of the situation. The company is actively engaged in discussions but does not speculate on outcomes.
Q:What are the assumptions behind the flat China growth guidance for 2026?
A:Roy Jakobs explained that China is expected to stabilize in 2026, with improvement in Personal Health sell-out trends but cautious outlook on health systems due to unpredictable tender conversions. Growth is expected to be driven more by North America and other regions.
Q:What structural changes have enabled better margin dynamics in Personal Health (PH)?
A:Charlotte Hanneman highlighted innovation, premiumization, strong commercial execution, and productivity as key drivers. Innovations like Sonicare and OneBlade, combined with disciplined execution, have improved margins.
Q:What drove the stronger-than-expected growth in Personal Health (PH) in Q4?
A:Charlotte Hanneman stated that growth was broad-based across businesses and geographies, with strong performance in grooming and benefits from lower comparables due to China destocking.
Q:What are the drivers for D&T and Connected Care (CC) demand in the U.S., and how sustainable are they?
A:Roy Jakobs mentioned strong investment in healthcare infrastructure, CapEx spending on monitoring and cybersecurity, and financial health of healthcare systems as key drivers. Patient volumes and procedures, especially in cardiology, are expected to sustain demand.
Q:Is the Q1 2026 margin decline similar to Q1 2025?
A:Charlotte Hanneman confirmed that the Q1 2025 margin decline is a good proxy for Q1 2026.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer on the Section 232 investigation, stating that no outcomes have been shared and not speculating on potential results. Additionally, while discussing the 2026 guidance, there was some vagueness in addressing how specific uncertainties like tariffs and dynamic global conditions would be managed in detail.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Capital Markets
Demand
Durga
EUR cash
EUR line
EUR productivity
Enterprise Informatics
Markets Day
Prestige
acquisition
business geography
cash balance
charge
commitment
currency
customer panel
enterprise
headwind EUR
health care
health system
income tax
informatics
insurance
margin productivity
margin tariff
measure tariff
outlook margin
payment
point basis
premium
productivity program
productivity tariff
regionalization
removal
sale line
scale
tariff headwind
tariff margin
tax asset
world
PHG Transcript
Koninklijke Philips N.V. (PHG) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call summary indicates strong order intake, sales growth, and a strategic focus on North America and international regions, with positive EBITDA margin expectations. The Q&A section highlights strong growth in the sleep business, effective cost mitigation strategies, and positive innovation momentum. Although there are challenges like cost inflation and centralized procurement in China, Philips appears well-positioned to manage these with AI and pricing strategies. Overall, the sentiment is positive, suggesting a potential stock price increase in the near term.
Koninklijke Philips N.V. (PHG) Q4 2025 Earnings Call Transcript
Unknown2-10
The earnings call reflects a mixed outlook: strong order growth and margin improvements indicate potential positives, but uncertainties around tariffs and vague management responses about future challenges temper enthusiasm. The Q&A reveals concerns about flat growth in China and potential headwinds from tariffs. The financial performance and strategic updates are not strong enough to drive a significant stock movement, thus a neutral sentiment is appropriate.
Koninklijke Philips N.V. (PHG) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call summary indicates strong financial performance with increased EPS, productivity savings, and positive sales growth, particularly in Personal Health. The Q&A section reveals effective strategies for mitigating risks, such as tariff impacts and competition in China. The company's cautious but optimistic outlook, combined with strategic partnerships and ongoing innovations, supports a positive sentiment. Despite some uncertainties, the overall tone is positive, suggesting a likely stock price increase in the short term.
Koninklijke Philips N.V. (PHG) Q2 2025 Earnings Call Transcript
Unknown7-29
The earnings call presents a mixed outlook. Strong points include growth in Personal Health and order strength in North America. However, uncertainties like tariff impacts, cautious guidance, and vague responses about future margins dampen positivity. The absence of a market cap makes it difficult to predict strong reactions. Overall, the sentiment is balanced, leading to a neutral stock price prediction.
PHG Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
